A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.
about
Current and emerging strategies for the prevention of graft-versus-host diseaseAcute graft-versus-host disease: a bench-to-bedside update.Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseGenomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Towards rational graft-versus-host disease prophylaxisThe addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialPharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte GlobulinApproaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationSirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience.Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized studySibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial.Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission.Thinking out of the box--new approaches to controlling GVHD.The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations.New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood TransplantationIncreased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation.Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity.Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.
P2860
Q27016541-48C079F0-127E-44D3-9619-10BE32FB9C17Q27687130-6C5C341A-5B73-44E2-930F-10CAEBC7C3F8Q33413498-7F9AF5EE-991C-4700-AA68-AE3FC6504FEBQ33424311-A4090A51-5AB4-4B8B-AFC6-54CAD5736FB8Q33816022-422577A6-1694-446A-BF1C-E697CDAC54FEQ34077792-56BCA4DC-422E-4847-89CC-322E8BFC474BQ34272554-D86AA806-0A31-406E-890B-CB0D8D3123FEQ34860077-A77065A3-85D8-4CED-AC1B-05C0ED24BC1CQ35207094-DCF6E8A6-1CE1-4125-A14C-0FBA201AE5A2Q35218515-523D9E47-AF5B-40BF-9D26-9D01C6E410C7Q35231363-2272C6AA-4962-459C-89E2-CE1B0318085CQ35499395-AAD5441A-D335-4333-ADEB-095B44B9DA31Q35800856-70D43401-A8DE-4606-B9C3-E6EE15F6D08AQ36223667-6CA962CC-A36C-4222-A666-B57F24863C9EQ36341861-28733C37-BB39-4B73-8EF8-2F1DFE88C65CQ36474050-9FDE5BAF-97C6-4963-9734-3BA9B487666FQ36662005-5C0C49C7-4E17-49DD-98A0-D0B3F734DFA5Q36734547-ECE29391-1355-462E-A9A0-B1F4D7831B23Q36777485-5D7C371B-36A3-4A67-969B-48E0AA629B20Q36838087-A9917AAA-FD61-477C-A62A-045991856FF8Q36891433-5966BAE4-987B-42B5-B8FD-70CA2C9A0AC6Q36892442-CEA36C56-18B3-4FC3-8442-9E73EF7D0AB6Q36980277-84793304-315A-4CF1-8CEA-F05553AF7788Q37022116-CF1829B3-6808-44F7-A48A-FCB167CFDCE1Q37348628-DFD0255C-4156-458D-B708-AD3621452613Q37618931-657948A2-992E-4FEA-9106-EEF95EBE2873Q38133244-B33CD964-1AE7-47FC-ABB3-B91B4922BEF6Q38175862-C43E283B-654E-45B3-997B-3CB7A62D2892Q38413246-FC3F1B08-76EC-4A75-852B-B60FDE76F578Q38773356-EAFCFC2F-974D-4875-8422-21F5AC62A09FQ38849186-84C5A0CA-C535-4F19-99CD-4544E7822500Q40486613-CE996F97-B561-4CF0-8661-4E7F906D0BC0Q40577820-FAE3D8CB-7E16-4EFD-B7BE-1524AC84C76CQ42175189-5288737D-C8C0-443A-8378-20A9B911815EQ47307319-F6E6EF37-3E64-4BC2-AD38-D744370520F1Q47952891-F11682BB-9E94-499F-848C-AC8936E59FC8Q48337187-60C8FD5C-A55A-4B50-B1E1-ED7CDD76385DQ50453045-512EED06-F83A-4FB8-8DD8-CCC9E1BA3B6DQ50927701-65085FDF-BF97-49CF-9A27-5725FE382EB9Q52927960-ACB37E16-8D00-4AFE-B16F-4F2641F730C4
P2860
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A randomized phase II study to ...... opoietic cell transplantation.
@ast
A randomized phase II study to ...... opoietic cell transplantation.
@en
type
label
A randomized phase II study to ...... opoietic cell transplantation.
@ast
A randomized phase II study to ...... opoietic cell transplantation.
@en
prefLabel
A randomized phase II study to ...... opoietic cell transplantation.
@ast
A randomized phase II study to ...... opoietic cell transplantation.
@en
P2093
P2860
P1433
P1476
A randomized phase II study to ...... opoietic cell transplantation.
@en
P2093
Anandaraman Veerapathran
Brian C Betts
Claudio Anasetti
Ernesto Ayala
Frederick L Locke
Heather Jim
Hugo F Fernandez
Janelle Perkins
Jongphil Kim
Joseph Pidala
P2860
P304
P356
10.3324/HAEMATOL.2012.067140
P577
2012-06-11T00:00:00Z